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Methods 
Study Design 
The HADS questionnaire includes seven items reflecting anxiety and seven items reflecting depression. 
Each item is answered by the patient on a four point (0–3) response category, and the possible scores 
range from 0 to 21 for anxiety and 0 to 21 for depression. A score of 0 to 7 for either subscale is 
regarded as being in the normal range, a score of 11 or higher indicating probable presence of the mood 
disorder and a score of 8 to 10 being suggestive of the respective state. 
 
Immune Cell Analysis 
For phenotypic and functional studies all samples from a single patient were thawed together and used 
in the same experiment. For MDSC analysis, surface staining of PBMCs for HLADR, CD15, CD14, and 
CD33 (BD Bioscience) was performed as described.1, 2  Total MDSC were defined as CD33+ HLA-DR low/-; 
PMN-MDSC were defined as CD33+ HLA-DR low/- CD14-CD15+; M-MDSC were defined as CD33+ HLA-DR 
low/- CD14+ CD15-, and I-MDSC were defined as CD33+ HLA-DR low/- CD14- CD15-.  Phenotypic analysis of 
regulatory T cells (Treg) cells in patient PBMCs was done by surface marker staining of CD3, CD4, (BD 
Bioscience) and CD25 (StemCell Technologies), followed by permeabilization using a FoxP3 buffer kit 
(eBioscience) and staining for FoxP3 (236A/E7 clone, eBioscience).  Results are expressed as percentage 
of CD25+hi/Foxp3+ cells out of total CD3+/CD4+ viable cells.3 For the analysis of T cell function, we 
accessed the ability of the T cells to produce IFN after stimulation with anti-CD3 and anti-CD28 coated 
Dynalbeads (25 l/ml) and 20U/mL of IL-2 as previously described.3 All flow data were acquired using 
Cellquest on a BD FACS Calibur and were analyzed using Cellquest software.  
3 
 
 
Table S1. Univariable Analysis of Surveillance Duration and Time to RECIST Progression 
                                                                                 Surveillance Duration                                    Time to RECIST Progression                                                             
Factor                                                          Median/Hazard Ratio1   95% C.I.              p2                             Median/Hazard Ratio1    95% C.I.                p2 
Age  1.02 0.98-1.05  .40 1.03  0.99-1.06 .11 
Gender 
 Male    14.9 10.6-28.5      9.4    7.4-13.5 
 Female  14.8   3.2-74.7    .64    9.7    3.2-22.2 .93 
KPS 
 100    13.9   9.0-25.0       9.1    4.1-13.1 
   90    31.6 11.4-69.7  13.5    8.6-17.2 
   80       5.2      3.0-9.2 .86   3.0    2.2-9.2 .86 
Time from diagnosis to metastatic disease 1.00 1.00-1.00 .96  1.00  1.00-1.00 .82 
No. IMDC risk factors 
    0    13.8   5.5-74.7  11.4    2.8-17.2 
 1    19.3 13.4-30.1  13.4    9.2-19.3 
 2-33     8.2      3.0-15.6 .02134   4.8    3.0-9.5 .00114 
IMDC prognostic group 
 Favorable (0 risk factors)    13.8   5.5-74.7  11.4    2.8-17.2 
 Intermediate/Poor (1-3 risk factors) 3  15.6    10.6-25.0 .28   9.2    6.2-13.4 .99 
No. MSKCC risk factors 
 0    13.8   5.5-74.7  11.4    2.8-17.2 
 1   20.7 12.3-33.3  12.3    8.6-19.3  
 2     7.4      3.0-15.6 .01844   6.2    2.3-9.5 .00244 
MSKCC prognostic group 
 Favorable (0 risk factors)      13.8   5.5-74.7  11.4    2.8-17.2 
 Intermediate (1-2 risk factors)   15.6     9.2-25.0 .30   9.2    7.4-13.4 .94 
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Metastatic Sites5 
 Lung only                                   19.3   9.1-74.7  11.4    3.0-17.2 
 Other organ(s) only    16.9 11.2-69.7  13.2    4.1-69.7 
 Both lung and other organs     9.0       3.0.-25.0 .0280   9.0    3.0-9.5 .13 
 
Number of organ sites with metastases 
 1     18.1 13.4-34.5  13.4    6.2-19.3 
 2    15.6   3.0-31.6    9.2    3.0-12.2 
 >26     7.9      2.8-8.4 .0239   7.9    2.7-N/A .11 
Tumor burden at baseline 
(sum in cm of RECIST measurements)   1.01 1.00-1.01  .15 1.00  0.99-1.01 .90 
 
1 Median outcomes are reported for categorical factors, hazard ratios from a proportional hazards model are reported for measured factors 
2 Logrank test for unordered categorical factors, logrank trend test for ordered categorical factors, Wald test for measured factors 
3 One patient had 3 risk factors 
4 0 or 1 risk factor versus >1 
5 25 patients had lung metastasis only; 14 had involved organs other than lung (10 patients had a single site, primarily lymph nodes, bone, or adrenal; 4 had 2 (n=2) or 3 (n=2) involved organs, primarily 
kidney with lymph nodes and/or bone); 19 had both 
6 6 patients had 3 and 2 had 4 
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Table S2. Multivariable Analysis 
Surveillance Duration 
                                                                        
                                  Factor                                                                  Hazard Ratio (95% C.I.)1           p2                        
 
Number of organ sites with metastases 
 1 versus 2 versus >2     1.61 (1.02-2.55)  .0414  
 
No. IMDC risk factors 
    0 or 1 versus >1 2.12 (1.03-4.34)  .0403     
 
 
 
Time to Progression 
                  Factor                                                      Hazard Ratio (95% C.I.)             p2 
No. Heng Poor Prognostic Factors 
        >1 versus 0 or 1        3.48 (1.68-7.22)       .0004 
 
 
1 The first group listed is the reference group. Hazard ratios being >1 indicate a decreased surveillance period for the other 
group(s) 
2 Wald test 
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Table S3: Peripheral Blood Immune Cell Populations at Baseline 
Median (IQR) percent 
of live cells 
Healthy Controls 
(n=20-22) 
Active Surveillance 
cohort (n=40) 
Immediate systemic therapy cohort 
(n=30-34)3 
p* p** 
MDSC 1.14 
(0.74-1.41) 
2.92 
(1.75-4.15) 
3.56 
(2.47-5.99) 
<.0001 <.0001 
Treg 1.44 
(1.25-1.86) 
0.59 
(0.35-0.97) 
2.02 
(1.32-2.58) 
<.0001 .0284 
CD3+ IFN-gamma T 
cells 
16.32 
(12.64-21.78) 
17.19 
(9.42-23.64) 
9.35 
(5.07-15.05) 
.50 .0004 
CD4+ IFN-gamma T 
cells 
15.84 
(12.46-21.14) 
16.78 
(9.07-22.13) 
7.67 
(4.43-11.80) 
.76 .0002 
 
Abbreviations: MDSC; myeloid- derived suppressor cells; Treg; regulatory T cells; IFN; interferon 
* Wilcoxon rank sum test for the comparison of active surveillance patients to controls 
** Wilcoxon rank sum test for the comparison of active surveillance patients to immediate systemic therapy cohort 
 
 
 
Table S4: Peripheral Blood Immune Cell Populations at Baseline, Month 6, Month 12 and at Last Assessment  
in Surveillance Cohort 
Median (IQR) percent 
of live cells 
Baseline Month 6 Month12 Last Assessment p* 
MDSC 2.92 
(1.75-4.15) 
2.84 
(1.25-6.47) 
2.45 
(1.19-4.40) 
2.71 
(1.21-5.04) 
0.90 
Treg 0.59 
(0.35-0.97) 
1.45 
(0.32-4.69) 
1.56 
(0.35-2.78) 
0.54 
(0.26-1.93) 
0.83 
CD3+ IFN-gamma T 
cells 
17.19 
(9.42-23.64) 
15.90  
(8.03-27.12) 
20.49  
(8.80-23.32) 
17.24  
(2.09-41.37) 
0.58 
CD4+ IFN-gamma T 
cells 
16.78 
(9.07-22.13) 
14.58  
(7.32-23.32) 
20.90                         
(7.02-23.10) 
15.90  
(2.04-45.23) 
0.52 
Abbreviations: MDSC; myeloid- derived suppressor cells; Treg; regulatory T cells; IFN; interferon. 
* Wilcoxon signed-rank test for absolute changes from pre-treatment to last assessment 
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Table S5: Participating Centers 
Study Site Principal Investigator Number of Patients 
Recruited 
Cleveland Clinic Taussig Cancer Institute Brian I. Rini, MD 32 
Fox Chase Cancer Center Elizabeth R. Plimack, MD 11 
USC Norris Comprehensive Cancer Center Tanya Dorff, MD 5 
Vall d'Hebron University Hospital  Cristina Suarez Rodriguez, MD 3 
Royal Marsden NHS Foundation Trust James Larkin, MD 1 
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